Zobrazeno 1 - 10
of 40
pro vyhledávání: '"J, Villacian"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
James G, Hakim, Jennifer, Thompson, Cissy, Kityo, Anne, Hoppe, Andrew, Kambugu, Joep J, van Oosterhout, Abbas, Lugemwa, Abraham, Siika, Raymond, Mwebaze, Aggrey, Mweemba, George, Abongomera, Margaret J, Thomason, Philippa, Easterbrook, Peter, Mugyenyi, A Sarah, Walker, Nicholas I, Paton, J, Villacian
Publikováno v:
The Lancet. Infectious diseases. 18(1)
Millions of HIV-infected people worldwide receive antiretroviral therapy (ART) in programmes using WHO-recommended standardised regimens. Recent WHO guidelines recommend a boosted protease inhibitor plus raltegravir as an alternative second-line comb
Autor:
Nicholas I, Paton, Cissy, Kityo, Jennifer, Thompson, Immaculate, Nankya, Leonard, Bagenda, Anne, Hoppe, James, Hakim, Andrew, Kambugu, Joep J, van Oosterhout, Mary, Kiconco, Silvia, Bertagnolio, Philippa J, Easterbrook, Peter, Mugyenyi, A Sarah, Walker, J, Villacian
Publikováno v:
The lancet. HIV. 4(8)
Cross-resistance after first-line antiretroviral therapy (ART) failure is expected to impair activity of nucleoside reverse-transcriptase inhibitors (NRTIs) in second-line therapy for patients with HIV, but evidence for the effect of cross-resistance
Autor:
Alejandro, Arenas-Pinto, Jennifer, Thompson, Godfrey, Musoro, Hellen, Musana, Abbas, Lugemwa, Andrew, Kambugu, Aggrey, Mweemba, Dickens, Atwongyeire, Margaret J, Thomason, A Sarah, Walker, Nicholas I, Paton, J, Villacian
Publikováno v:
Journal of neurovirology. 22(1)
Sensory peripheral neuropathy (PN) remains a common complication in HIV-positive patients despite effective combination anti-retroviral therapy (ART). Data on PN on second-line ART is scarce. We assessed PN using a standard tool in patients failing f
Autor:
Nicholas I, Paton, Cissy, Kityo, Anne, Hoppe, Andrew, Reid, Andrew, Kambugu, Abbas, Lugemwa, Joep J, van Oosterhout, Mary, Kiconco, Abraham, Siika, Raymond, Mwebaze, Mary, Abwola, George, Abongomera, Aggrey, Mweemba, Hillary, Alima, Dickens, Atwongyeire, Rose, Nyirenda, Justine, Boles, Jennifer, Thompson, Dinah, Tumukunde, Ennie, Chidziva, Ivan, Mambule, Jose R, Arribas, Philippa J, Easterbrook, James, Hakim, A Sarah, Walker, Peter, Mugyenyi, J, Villacian
Publikováno v:
The New England journal of medicine. 371(3)
BACKGROUND: The efficacy and toxic effects of nucleoside reverse-transcriptase inhibitors (NRTIs) are uncertain when these agents are used with a protease inhibitor in second-line therapy for human immunodeficiency virus (HIV) infection in resource-l
Publikováno v:
Journal of the International AIDS Society. 15
Highly effective regimens have drastically improved HIV morbidity and mortality although anti-retro viral resistance remains a limiting factor in disease management. Therefore, analysis of large sequence datasets may provide better insight into drug
Publikováno v:
Journal of the International AIDS Society
Purpose of the study: Darunavir (DRV) is an HIV protease inhibitor (PI) first approved in 2006. This analysis evaluated the prevalence of DRV resistance associated mutations (RAMs) in clinical samples submitted for routine resistance testing to asses
Publikováno v:
Journal of the International AIDS Society
Background: Interference of clinical laboratory assays by endogenous & exogenous substances in the blood is well known. To date, there are no clear guidelines on the testing of lipemic or bilirubinemic (icteric) plasma in clinical laboratories. A con
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.